Market Access News | pharmaphorum

News

AbbVie loses bid to block 340B law in Mississippi

Battle lines are being drawn on 340B rebates as AbbVie loses a bid to block a Mississippi law seeking to retain discounts for contract pharmacies.

News

AZ halts UK investment, and Lilly, Sanofi follow suit

After MSD's bombshell retreat from a big UK investment plan, AstraZeneca, Lilly, and Sanofi are also pressing pause on new projects.

News

Reaction to MSD's UK exit as government tries to renew talks

The UK government is reported to be trying to restart talks over drug pricing and rebates after MSD's shock decision to scrap a £1bn investment spend.

News

Intercept pulls Ocaliva off the market in the US

Alfasigma's $800m buyout of Intercept is starting to look like a poor bet as its only product, Ocaliva, is pulled from the market.

News

J&J claims FDA okay for bladder cancer drug TAR-200

Johnson & Johnson has brought its bladder cancer drug TAR-200 to the US market, a year after its prospects were dented by a negative phase 3 readout.

News

Pharma says UK is 'tumbling down' rankings for investment

The UK is losing out to competitors in attracting investment in R&D, clinical trials, and capital projects, says a report from the ABPI pharma group.

AbbVie loses bid to block 340B law in Mississippi

AZ halts UK investment, and Lilly, Sanofi follow suit

Reaction to MSD's UK exit as government tries to renew talks

Intercept pulls Ocaliva off the market in the US

J&J claims FDA okay for bladder cancer drug TAR-200

Pharma says UK is 'tumbling down' rankings for investment

Lilly partners with Hims & Hers on obesity drug sales

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks